Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesDiaceutics PLC

Diaceutics PLC

Healthcare Health Information Services
PortfolioPortfolio WatchlistWatchlist
Company price
200.5 GBX 1.50 ( 0.75%)
Last update at 2026-10-27T16:35:00Z
VOLUME
322094
Market Cap
140.06M

Momentum Score

…

Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies. The company offers DXRX, a diagnostic commercialization platform for precision medicine that integrates multiple pipelines of diagnostic testing data from a network of laboratories. It also provides DXRX data solutions, including DXRX Signal, which delivers an actionable alert of a testing behavior for making treatment decisions; DXRX Physician Mapping that examines physician testing behavior using patient level data to determine testing rates, methodology, and physician to lab relationship; DXRX Lab Mapping that offers insights into labs currently testing patients diagnosed with a specific disease or biomarker; and DXRX Disease Testing Rate Tracker, which delivers biomarker testing rate reports. In addition, the company offers professional services, such as market landscape, implementation, and consulting services. It operates in North America, the United Kingdom, Europe, Asia, and internationally. The company was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
198.00
Low
200.50
High
52 Week Price Range
110.00
Low
176.25
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
199.00
Dividend Yield
-
Revenue TTM
34.40M
Revenue Per Share
0.41
Gross Profit TTM
29.63M
Debt / Equity
0.03
ROE
-4.00%
Net Debt
-11.68M
ROCE
-4.54%
Diluted EPS TTM
-0.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -1.91M -2.44M 0.56M 0.46M -0.68M
Net income -1.70M -1.75M 0.72M 0.56M 0.26M
Selling general administrative 30.74M 22.78M 16.28M 10.38M 10.02M
Selling and marketing expenses - 4.77M - - -
Gross profit 28.27M 19.71M 16.74M 10.73M 9.46M
Reconciled depreciation 4.63M 4.77M 3.01M 1.80M 0.81M
Ebit -1.85M -2.41M 0.57M 0.55M -0.24M
Ebitda 2.77M 2.36M 3.69M 2.35M 0.57M
Depreciation and amortization 4.63M 4.77M 3.12M 1.80M 0.81M
Operating income -2.46M -3.02M 0.57M 0.55M -0.24M
Other operating expenses 34.61M 26.72M 18.93M 13.39M 12.97M
Interest expense 0.05M 0.07M 0.12M 0.09M 0.04M
Tax provision -0.20M -0.69M -0.16M -0.10M -0.94M
Interest income 0.60M 0.65M 0.11M 0.00M 0.03M
Net interest income 0.55M 0.58M -0.01M -0.09M -0.01M
Income tax expense -0.20M -0.69M -0.16M -0.10M -0.94M
Total revenue 32.16M 23.70M 19.50M 13.94M 12.70M
Total operating expenses 30.73M 22.72M 16.17M 10.18M 9.73M
Cost of revenue 3.89M 3.99M 2.76M 3.21M 3.23M
Total other income expense net 0.55M 0.58M -0.01M -0.09M -0.44M
Net income from continuing ops -1.70M -1.75M 0.72M 0.56M 0.26M
Net income applicable to common shares - - 0.72M 0.56M 0.26M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 48.62M 46.34M 48.26M 45.01M 43.52M
Intangible assets 15.41M 15.26M 15.22M 12.82M 9.36M
Other current assets 1.82M 1.25M - 10.39M 8.36M
Total liab 8.76M 5.56M 5.74M 4.36M 3.28M
Total stockholder equity 39.86M 40.79M 42.51M 40.65M 40.24M
Deferred long term liab - - 0.18M 0.22M 0.42M
Other current liab 5.93M 2.29M 2.87M 1.84M 2.33M
Common stock 0.17M 0.17M 0.17M 0.17M 0.17M
Capital stock 0.17M 0.17M 0.17M 0.17M 0.17M
Retained earnings 40.62M 4.04M 5.34M 4.08M 3.19M
Other liab - - 0.79M 0.45M 0.37M
Other assets - - 0.22M 0.22M 0.72M
Cash 12.74M 16.67M 19.84M 19.68M 25.25M
Total current liabilities 7.76M 4.38M 3.75M 2.63M 2.92M
Current deferred revenue - 0.41M - - -
Net debt -11.68M -15.46M -18.51M -18.11M -25.14M
Short term debt 0.15M 0.15M 0.12M 0.28M 0.12M
Short long term debt - - 0.00M 0.13M 0.12M
Short long term debt total 1.06M 1.21M 1.33M 1.56M 0.12M
Other stockholder equity -0.31M 36.81M 37.00M 36.40M 36.88M
Property plant equipment - - 2.09M 2.13M 0.24M
Total current assets 29.53M 28.04M 30.90M 30.06M 33.62M
Net tangible assets - - 27.47M 28.04M 31.30M
Net receivables 14.96M 10.13M 5.79M 9.92M 7.78M
Inventory - 0.00M - - -
Accounts payable 1.22M 1.06M 0.76M 0.51M 0.47M
Accumulated other comprehensive income -0.63M -0.24M - - -0.16M
Common stock total equity - - - - 0.17M
Non currrent assets other - 15.26M - - -
Non current assets total 19.09M 18.30M 17.36M 14.95M 9.90M
Capital lease obligations 1.06M 1.21M 1.33M 1.43M -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -4.03M -4.21M -4.76M -5.60M -6.29M
Change to liabilities - - 1.27M -0.16M -0.06M
Total cashflows from investing activities -4.03M -4.21M -4.76M -5.60M -6.29M
Net borrowings - - -0.16M -0.10M -0.10M
Total cash from financing activities -0.06M -0.24M -0.19M -0.27M 19.61M
Net income -1.91M -1.75M 0.56M 0.46M -0.68M
Change in cash -3.92M -3.17M 0.17M -5.58M 13.54M
Begin period cash flow 16.67M 19.84M 19.68M 25.25M 11.72M
End period cash flow 12.74M 16.67M 19.84M 19.68M 25.25M
Total cash from operating activities 0.65M 1.31M 5.10M 0.57M 0.25M
Issuance of capital stock 0.14M 0.00M 0.13M 0.00M 19.61M
Depreciation 4.63M 4.77M 3.01M 1.80M 0.81M
Other cashflows from investing activities -3.93M -4.08M 0.11M 0.11M 0.11M
Change to account receivables -4.68M -2.16M -1.59M -1.50M 0.55M
Sale purchase of stock 0.00M -0.05M -0.10M -0.17M 19.61M
Other cashflows from financing activities -0.00M -0.01M -0.22M -0.10M -6.29M
Change to netincome - - 1.69M -0.13M -1.30M
Capital expenditures 4.63M 4.86M 4.87M 5.60M 6.29M
Change in working capital -1.30M -1.54M -0.33M -1.66M 0.49M
Stock based compensation 1.02M 0.45M 0.54M 0.37M 0.29M
Other non cash items -1.79M -0.62M 1.32M 0.09M 0.02M
Free cash flow -3.98M -3.54M 0.23M -5.03M -6.04M

Peer Comparison*

Sector: Healthcare Industry: Health Information Services

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
DXRX
Diaceutics PLC		 1.50
0.75%		 200.50 - 178.57 4.07 3.51 3.53 35.21
CRW
Craneware Plc		 2.00
0.18%		 1088.00 29.63 11.26 2.36 1.84 2.89 9.61
OPT
Optima Health plc		 -
-%		 243.50 15.04 13.59 1.42 0.96 1.52 10.54
KOO
Kooth plc		 -
-%		 189.50 16.06 11.38 0.64 1.42 0.35 2.52
COG
Cambridge Cognition Holdings Plc		 -
-%		 28.00 - 12.84 2.01 7.68 2.10 100.23

Profile*

Diaceutics PLC

Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies. The company offers DXRX, a diagnostic commercialization platform for precision medicine that integrates multiple pipelines of diagnostic testing data from a network of laboratories. It also provides DXRX data solutions, including DXRX Signal, which delivers an actionable alert of a testing behavior for making treatment decisions; DXRX Physician Mapping that examines physician testing behavior using patient level data to determine testing rates, methodology, and physician to lab relationship; DXRX Lab Mapping that offers insights into labs currently testing patients diagnosed with a specific disease or biomarker; and DXRX Disease Testing Rate Tracker, which delivers biomarker testing rate reports. In addition, the company offers professional services, such as market landscape, implementation, and consulting services. It operates in North America, the United Kingdom, Europe, Asia, and internationally. The company was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.

Building Two, Belfast, United Kingdom, BT9 6GW

https://www.diaceutics.com

213

Name Title Year Born
Mr. Peter Keeling Founder, CEO & Exec. Director 1962
Mr. Ryan Keeling Chief Innovation Officer & Exec. Director 1983
Mr. Nicholas Stewart Roberts CFO & Director 1983
Ms. Julie Browne Chief Operating Officer NA
Ms. Gillian Shaw Gen. Counsel NA
Ms. Jillian Beggs VP of Sales & Marketing NA
Ms. Norma Thompson Global Head of HR NA
Mr. Jordan Clark Chief Commercial Officer NA
Ms. Susanne Munksted Chief Precision Officer NA
Mr. Scott Morrison Head of Data Science NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DHT-U
CAD 13.53
+16.44%
LIF
CAD 22.04
+8.62%
TOI
CAD 103.80
+7.09%
CRON
CAD 5.26
+6.69%
CIA
CAD 2.04
+6.25%
ITH
CAD 1.61
-34.02%
IFOS
CAD 1.65
-22.90%
TNZ
CAD 49.70
-19.58%
KEEL
CAD 2.36
-19.45%
GIL
CAD 49.36
-18.33%

Equity Sectors*

  • Basic Materials

    -2.18%

  • Communication Services

    +0.95%

  • Consumer Cyclical

    -2.25%

  • Consumer Defensive

    -0.68%

  • Energy

    -2.93%

  • Financial Services

    -2.26%

  • Healthcare

    -0.46%

  • Industrials

    -3.70%

  • Real Estate

    -0.06%

  • Technology

    -3.32%

  • Utilities

    -0.50%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…